Friday, 26 June 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 26 June 2026
News

Two days, two big deals for Arrotex

Posted 26 June 2026 AM

Arrotex is on a roll, signing yet another agreement to bring an innovative medicine to Australia and New Zealand.

This deal is with Chinese pharma CStone Pharmaceuticals and licenses "an anti-PD-L1 monoclonal antibody treatment for lung and other types of cancer," likely referring to sugemalimab, which is marketed as Cejemly in Europe and the UK.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (18)

Access & Reimbursement (2)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (6)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.